» Articles » PMID: 22406983

Targeting of 4-1BB by Monoclonal Antibody PF-05082566 Enhances T-cell Function and Promotes Anti-tumor Activity

Abstract

4-1BB (CD137, TNFRSF9) is a costimulatory receptor expressed on several subsets of activated immune cells. Numerous studies of mouse and human T cells indicate that 4-1BB promotes cellular proliferation, survival, and cytokine production. 4-1BB agonist mAbs have demonstrated efficacy in prophylactic and therapeutic settings in both monotherapy and combination therapy tumor models and have established durable anti-tumor protective T-cell memory responses. PF-05082566 is a fully human IgG2 that binds to the extracellular domain of human 4-1BB with high affinity and specificity. In preclinical studies, this agonist antibody demonstrated its ability to activate NF-κB and induce downstream cytokine production, promote leukocyte proliferation, and inhibit tumor growth in a human PBMC xenograft tumor model. The mechanism of action and robust anti-tumor efficacy of PF-05082566 support its clinical development for the treatment of a broad spectrum of human malignancies.

Citing Articles

A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Piha-Paul S, Olwill S, Hamilton E, Tolcher A, Pohlmann P, Liu S Clin Cancer Res. 2024; 31(2):288-298.

PMID: 39235868 PMC: 11739778. DOI: 10.1158/1078-0432.CCR-24-1552.


Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.

Matson A, Hullsiek R, Dixon K, Wang S, Lindstedt A, Friess R J Immunother Cancer. 2024; 12(7).

PMID: 39053944 PMC: 11284835. DOI: 10.1136/jitc-2024-008959.


Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation.

Ahn M, Kim E, Choi Y, Chae C, Kim P, Kim S PLoS One. 2024; 19(6):e0305261.

PMID: 38923962 PMC: 11207149. DOI: 10.1371/journal.pone.0305261.


Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents.

Kopp A, Guan J, Johnston C, Vance S, Legg J, Galson-Holt L AAPS J. 2024; 26(4):68.

PMID: 38862748 PMC: 11497593. DOI: 10.1208/s12248-024-00937-3.


Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.

Ma Y, Luo F, Zhang Y, Liu Q, Xue J, Huang Y Cell Rep Med. 2024; 5(2):101414.

PMID: 38330942 PMC: 10897605. DOI: 10.1016/j.xcrm.2024.101414.


References
1.
Ascierto P, Simeone E, Sznol M, Fu Y, Melero I . Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010; 37(5):508-16. DOI: 10.1053/j.seminoncol.2010.09.008. View

2.
Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

3.
Gladue R, Paradis T, Cole S, Donovan C, Nelson R, Alpert R . The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011; 60(7):1009-17. PMC: 11028430. DOI: 10.1007/s00262-011-1014-6. View

4.
Li F, Ravetch J . Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011; 333(6045):1030-4. PMC: 3164589. DOI: 10.1126/science.1206954. View

5.
Cheever M . Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008; 222:357-68. DOI: 10.1111/j.1600-065X.2008.00604.x. View